Bengaluru, India, February 27, 2022 – Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that it has entered into a definitive agreement with its partner Viatris Inc. Accordingly,…
Biotechnology major Biocon on Tuesday said it has inked a pact with Saudi Arabia-based drug firm Tabuk Pharmaceutical Manufacturing Company to commercialise select speciality products in the Middle East region.…
New Delhi : Calling upon the pharma industry leaders to collaborate towards building a much more robust and thriving innovation ecosystem, Amitabh Kant,CEO, NITI Aayog asked the Indian pharmaceutical industry…
Biopharmaceutical major Biocon has its eyes set on the US insulin market, which is expected to grow to $29.9 billion by 2025, with its interchangeable biosimilar product Semglee that has…
Biocon and its partner Viatris said Express Scripts, a leading Pharmacy benefit manager (PBM) Express in US, will be listing interchangeable biosimilar Insulin Glargine sold under brand name Semglee as…
New Delhi, Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about…
